Polygon Labs finalized its acquisition of Coinme on October 14, expanding its payments platform with U.S. money movement infrastructure. Coinme operates in 48 states with multiple licenses but faces a multistate regulatory order requiring it to cease virtual currency kiosk operations in Georgia by January 1, 2027, and pay $2.5 million in penalties. The acquisition supports Polygon's strategy to enhance fiat on- and off-ramps, wallet infrastructure, and payment orchestration for its customers. Despite regulatory hurdles, Coinme can continue other money transmission services in Georgia.
Polygon's acquisition of Coinme coincides with a day where only 6 of 50 major cryptocurrencies on Pluang rose. For readers following crypto markets, here is Pluang's snapshot as of Oct 14, 2026 22:02 WIB: BAL (Balancer) led gains with a price of Rp16.297 and a 1-day change of +11.14%, while ONE (Harmony) and XTZ (Tezos) declined by -8.30% and -8.13% respectively, with significant sell order activity and typical hold times ranging from 85 to 152 days.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
